Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 725 of 6351
-
New hope for hard-to-treat breast cancer: experimental combo shows promise
Disease control OngoingThis study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally ad…
Phase 2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Can a pill target multiple Hard-to-Treat cancers?
Disease control Recruiting nowThis is a phase 1, multicentre, first-in-human, open-label, dose-escalation/consolidation study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered JBI-778 in EGFR mutated lung cancer patients with or without brain metastasi…
Phase 1 • Sponsor: Jubilant Therapeutics India Limited • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for asthma sufferers: dupilumab may beat higher steroid doses
Disease control OngoingThis study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breathe. Uncontrolled asthma means that patients are still having frequent symptoms w…
Phase 4 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Pregnancy vaccine shields newborns from RSV: Real-World data reveals impact
Vaccine OngoingThis study will be conducted in collaboration with a research network of independent hospital sites to evaluate the vaccine effectiveness (VE) and impact of ABRYSVO vaccination during pregnancy in a real-world population over multiple seasons, which began in 2024 across Argentina…
Sponsor: Pfizer • Aim: Vaccine
Last updated Jun 27, 2026 12:34 UTC
-
New hope for Hard-to-Treat blood cancer: experimental drug shows promise
Disease control OngoingAll subjects will receive GR1803 injection until intolerable toxicity or investigator-assessed disease progression occurs (except in cases of disease progression due to discontinuation of the drug as a result of an adverse event) or until the subject has been administered the dru…
Phase 2 • Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New magnetic therapy could offer gentler depression treatment
Symptom relief Recruiting nowThe purpose of this study is to compare the efficacy and side effects magnetic seizure therapy (MST) and electroconvulsive therapy (ECT) in Bipolar Depression (MST-BpD) and Treatment Resistant Depression (MST-TRD).
Sponsor: Joao L. DeQuevedo • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
Could gut bacteria hold the key to childhood OCD?
Knowledge-focused Recruiting nowThis study aims to investigate the characteristics of the microbiota-gut-brain axis in pediatric patients with obsessive-compulsive disorder (OCD) through performing an integrated analysis of gut microbiota, serum metabolomics, neuroimaging and electroencephalography (EEG), condu…
Sponsor: Shanghai Mental Health Center • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Pedaling against Parkinson's: Exercise-Genetics trial launches
Disease control Recruiting nowThe proposed multi-site, Genetics and Aerobic Exercise to Slow PD (GEARS) Trial will, for the first time, determine the interplay between genetics and exercise in altering PD progression. In sum, 200 PD patients will be recruited from the Cleveland and Salt Lake City metro areas …
Sponsor: Jay Alberts • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Heat and immunotherapy join forces against bile duct cancer
Disease control Recruiting nowThe present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial. Patients with unresectable perihilar and/or ductal CCA with indication for bile duct stenting and palliative systemic therapy as determined by the local multid…
Phase 2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New pill-and-immunotherapy cocktail takes on advanced tumors
Disease control Recruiting nowThis study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be ad…
Phase 1/2 • Sponsor: 7 Hills Pharma, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for wet AMD: two novel drugs enter final testing phase
Disease control OngoingA Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
Phase 3 • Sponsor: Kodiak Sciences Inc • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New study pits two drug combos against stubborn thyroid cancer
Disease control Recruiting nowThis phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid cancer that does not respond to treatment (refractory) and which expresses a BRAF V600E mutation. Cabozantinib is in a c…
Phase 3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New injection aims to tame lupus when standard treatments fail
Disease control OngoingThis is a single-arm, open-label, multicenter, phase 1/2 clinical study to assess the safety and efficacy of GC012F Injection in subjects with refractory Systemic Lupus Erythematosus (SLE).
Phase 1/2 • Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Sep 10, 2026 05:00 UTC
-
Experimental triple therapy aims to tame leukemia without intensive chemo
Disease control Recruiting nowThis phase I trial tests the safety, side effects, and best dose of iadademstat when given together with azacitidine and venetoclax in treating patients with newly diagnosed acute myeloid leukemia (AML). Iadademstat inhibits the LSD1 protein and may lead to inhibition of cell gro…
Phase 1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New immunotherapy combo shows promise for tough cancers
Disease control Recruiting noweVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors.
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New CAR-T therapy targets Tough-to-Treat myeloma
Disease control Recruiting nowDespite recent therapeutic advances, multiple myeloma (MM) remains an incurable disease. Although survival has improved, there are nevertheless diminishing durations of response to each subsequent line of therapy. This highlights the need for further therapeutic innovation. BCMA-…
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
A simple blood test could spot kidney transplant rejection early
Diagnosis Recruiting nowIn France, 3,500 kidney transplants are carried out per year; and 40,000 people succeed in 2019 with a kidney transplant. Despite regular medical monitoring, nearly 30% of transplant patients will develop rejection. Currently, only solid biopsy of the graft makes it possible to e…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
New shot could help control breast cancer in younger women
Disease control OngoingThe study is to assess the safety, efficacy and pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.
Phase 3 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New hope for nerve disease patients: drug may replace monthly IV treatments
Disease control Recruiting nowThe purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will be for a maximum of 109 weeks including screening, treatment phases, and follow-up.
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New triple therapy aims to boost leukemia remission
Disease control Recruiting nowTo compare the efficacy and safty of ABC-14 regimen with the traditional "3+7" regimen or AB-14 regimen in the treatment of newly diagnosed acute myeloid leukaemia
Phase 2 • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC